Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients

  • Despite multimodal treatment, the prognosis of high-grade gliomas is grim. As tumor growth is critically dependent on new blood vessel formation, antiangiogenic treatment approaches offer an innovative treatment strategy. Bevacizumab, a humanized monoclonal antibody, has been in the spotlight of antiangiogenic approaches for several years. Currently, MRI including contrast-enhanced T1-weighted and T2/fluid-attenuated inversion recovery (FLAIR) images is routinely used to evaluate antiangiogenic treatment response (Response Assessment in Neuro-Oncology criteria). However, by restoring the blood–brain barrier, bevacizumab may reduce T1 contrast enhancement and T2/FLAIR hyperintensity, thereby obscuring the imaging-based detection of progression. The aim of this review is to highlight the recent role of imaging biomarkers from MR and PET imaging on measurement of disease progression and treatment effectiveness in antiangiogenic therapies. Based on the reviewed studies, multimodal imaging combining standard MRI with new physiological MRI techniques and metabolic PET imaging, in particular amino acid tracers, may have the ability to detect antiangiogenic drug susceptibility or resistance prior to morphological changes. As advances occur in the development of therapies that target specific biochemical or molecular pathways and alter tumor physiology in potentially predictable ways, the validation of physiological and metabolic imaging biomarkers will become increasingly important in the near future.

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Author:Markus Hutterer, Elke Hattingen, Christoph PalmORCiDGND, Martin Andreas Proescholdt, Peter Hau
Parent Title (English):Neuro-Oncology
Document Type:Article
Year of first Publication:2015
Release Date:2019/12/20
Tag:Antiangiogenic treatment; High-grade glioma; MRI; Multimodal response assessment; PET
GND Keyword:Gliom; Antiangiogenese; Bildgebendes Verfahren; Biomarker
First Page:784
Last Page:800
Institutes:Fakultät Informatik und Mathematik
Regensburg Center of Biomedical Engineering - RCBE
Fakultät Informatik und Mathematik / Regensburg Medical Image Computing (ReMIC)
research focus:Lebenswissenschaften und Ethik
Licence (German):Keine Lizenz - Es gilt das deutsche Urheberrecht: § 53 UrhG